Evidence map›Paper›PMID 35209951›Full record

ArticleTrials2022

The "Blood pressure and oxygenation targets in post resuscitation care, a randomized clinical trial": design and statistical analysis plan.

Jesper Kjaergaard, Henrik Schmidt, Jacob E Møller, Christian Hassager

Registry-linked trialOpen access · goldAbstract readClinical Trial Protocol
In one paragraph

Article in Trials, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03141099 (Blood Pressure and Oxygenation Targets in Post-resuscitation Care, a Randomized Clinical Trial), which is not on this map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03141099 nacompletednot on this map

Blood Pressure and Oxygenation Targets in Post-resuscitation Care, a Randomized Clinical Trial

TypeinterventionalSponsorJesper KjaergaardRan2017 to 2022Enrolled802ConditionsOut-of-Hospital Cardiac Arrest, Blood Pressure, Hemodynamic InstabilityArmsLow normal MAP, High normal MAP, Low normal PaO2., High normal PaO2
3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 23 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Jesper KjaergaardDepartment of Cardiology, The Heart Centre, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark. jesper.kjaergaard.05@regionh.dk.ORCID http://orcid.org/0000-0001-5244-0399
Henrik SchmidtDepartment of Cardiothoracic Intensive Care, Odense University Hospital, Odense, Denmark.
Jacob E MøllerDepartment of Cardiology, The Heart Centre, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
Christian HassagerDepartment of Cardiology, The Heart Centre, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
Odense University Hospital · DKUniversity of Copenhagen · DK

Funding

Novo Nordisk Fonden NNF17OC0028706
6 · The paper itself

Abstract

backgroundComatose patients admitted after resuscitation from cardiac arrest have a significant risk of poor outcome due to hypoxic brain injury. While numerous studies have investigated and challenged the target temperature as the efficacious part of the guideline endorsed Targeted Temperature Management (TTM) protocols, our knowledge and how the remaining parts of the TTM are optimized remain sparse. The present randomized trial investigated two aspects of the TTM protocol: target blood pressure during the ICU stay and oxygenation during mechanical ventilation. Furthermore, the efficacy of device-based post-TTM fever management is addressed.

methodsInvestigator-initiated, dual-center, randomized clinical trial in comatose OHCA patients admitted to an intensive cardiac care unit. Patients are eligible for inclusion if unconscious, older than 18 years of age, and have return of spontaneous circulation for more than 20 min.

interventionallocation 1:1:1:1 into a group defined by (a) blood pressure targets in double-blind intervention targeting a mean arterial blood pressure of 63 or 77 mmHg and (b) restrictive (9-10 kPa) or liberal (13-14 kPa) of arterial oxygen concentration during mechanical ventilation. As a subordinate intervention, device-based active fever management is discontinued after 36 h or 72. Patients will otherwise receive protocolized standard of care according to international guidelines, including targeted temperature management at 36 °C for 24 h, sedation with fentanyl and propofol, and multimodal neuro-prognostication. Primary endpoint: Discharge from hospital in poor neurological status (Cerebral Performance category 3 or 4) or death, whichever comes first. SECONDARY OUTCOMES: Time to initiation of renal replacement therapy or death, neuron-specific enolase (NSE) level at 48 h, MOCA score at day 90, Modified Ranking Scale (mRS) and CPC at 3 months, NT-pro-BNP at 90 days, eGFR and LVEF at 90 days, daily cumulated vasopressor requirement during ICU stay, and need for a combination of vasopressors and inotropic agents or mechanical circulatory support. DISCUSSION: We hypothesize that low or high target blood pressure and restrictive and liberal oxygen administration will have an impact on mortality by reducing the risk and degree of hypoxic brain injury. This will be assessment neurological outcome and biochemical and neuropsychological testing after 90 days.

trial registrationClinicalTrials.gov NCT03141099. Registered on May 2017 (retrospectively registered).

Indexed as

Heart ArrestHypothermia, InducedOut-of-Hospital Cardiac ArrestBlood PressureDouble-Blind MethodHumansRandomized Controlled Trials as TopicResuscitationTreatment OutcomeBlood pressure targetsCardiac arrestOxygenation targetsPost-cardiac arrest careTargeted temperature management

Identifiers

PMID35209951
PMCPMC8867659
OpenAlexW4214539145

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.